Compare SPIR & CNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SPIR | CNTX |
|---|---|---|
| Founded | 2012 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 292.9M | 283.9M |
| IPO Year | 2020 | 2021 |
| Metric | SPIR | CNTX |
|---|---|---|
| Price | $10.88 | $2.83 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 7 |
| Target Price | ★ $13.10 | $6.00 |
| AVG Volume (30 Days) | 383.7K | ★ 881.8K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 69.33 |
| EPS | ★ 2.31 | N/A |
| Revenue | ★ $110,451,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $7.07 | N/A |
| P/E Ratio | $4.71 | ★ N/A |
| Revenue Growth | ★ 13.15 | N/A |
| 52 Week Low | $6.60 | $0.49 |
| 52 Week High | $14.53 | $3.62 |
| Indicator | SPIR | CNTX |
|---|---|---|
| Relative Strength Index (RSI) | 57.83 | 55.44 |
| Support Level | $10.48 | $2.07 |
| Resistance Level | $12.50 | N/A |
| Average True Range (ATR) | 0.63 | 0.30 |
| MACD | 0.20 | 0.02 |
| Stochastic Oscillator | 78.52 | 50.00 |
Spire Global Inc is a provider of space-based data, analytics, and Space Services, offering datasets and powerful insights about Earth from the ultimate vantage point of space so that organizations can make decisions with confidence, accuracy, and speed. It generates revenue from four solutions: Maritime, Aviation, Weather, and Space Services. It offers the following three data solutions to customers; Maritime-precise space-based data used for accurate ship monitoring, ship safety, and route optimization, Aviation-precise space-based data used for accurate aircraft monitoring, aircraft safety, and route optimization, and Weather-precise space-based data used for accurate weather forecasting.
Context Therapeutics Inc is a clinical-stage biopharmaceutical company advancing medicines for solid tumors. The development team is advancing a pipeline of various therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer. The company's preclinical program, CTIM-76, is an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody (bsAb) that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.